Why has active immunotherapy not worked in lung cancer?

Annals of Oncology

Volumn 26, Issue 11, 2015, Pages 2213-2220

  Thomas, A ^a   Giaccone, Giuseppe ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Active immunotherapy; immune checkpoint; nonsmall cell lung cancer; tumor mediated immunosuppression; vaccines

Indexed keywords

BELAGENPUMATUCEL L; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 3; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; TECEMOTIDE; TRANSFORMING GROWTH FACTOR BETA; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL EXPANSION; CELLULAR IMMUNITY; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; HUMAN; HUMORAL IMMUNITY; IMMUNE CHECKPOINT; IMMUNOLOGICAL PARAMETERS; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; NON SMALL CELL LUNG CANCER; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ACTIVE IMMUNOTHERAPY; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; LUNG NEOPLASMS; PROCEDURES; T LYMPHOCYTE; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; T-LYMPHOCYTES;

EID: 84947741236     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv323     Document Type: Review

References (65)

1. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
2. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
3. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012; 13: e301-e310.
4. Shepherd FA, Douillard JY, Blumenschein GR, Jr. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol 2011; 6: 1763-1773.
5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med 2010; 363: 411-422.
6. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-424.
7. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4721-4730.
8. Giaccone G, Bazhenova L, Nemunaitis J et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC). In Presented at 2013 European Cancer Congress; 27 September-1 October 2013; Late-Breaking Abstract 2. Amsterdam, The Netherlands.
9. North S, Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 2005; 4: 249-257.
10. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non-small cell lung cancer. Clin Cancer Res 2007; 13: s4652-s4654.
11. Butts C, Murray N, Maksymiuk A et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23: 6674-6681.
12. Butts C, Maksymiuk A, Goss G et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011; 137: 1337-1342.
13. Butts C, Murray RN, Smith CJ et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 2010; 11: 391-395.
14. Butts C, Socinski MA, Mitchell PL et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 59-68.
15. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25 (suppl 18): abstr 7554.
16. Vansteenkiste J, Zielinski M, Linder A et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013; 31: 2396-2403.
17. Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer. GSK Press Release. 2 April 2014.
18. Chen HL, Gabrilovich D, Tampe R et al. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996; 13: 210-213.
19. Singal DP, Ye M, Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer 1996; 68: 629-636.
20. Johnsen A, France J, Sy MS, Harding CV. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 1998; 58: 3660-3667.
21. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
22. Baba T, Hanagiri T, Ichiki Y et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 2007; 98: 1795-1802.
23. Hiraki A, Kaneshige T, Kiura K et al. Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Clin Cancer Res 1999; 5: 933-936.
24. Sugaya M, Takenoyama M, Osaki T et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 2002; 122: 282-288.
25. Passlick B, Izbicki JR, Simmel S et al. Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 1994; 30A: 376-381.
26. Kikuchi E, Yamazaki K, Torigoe T et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007; 98: 1424-1430.
27. Traversari C, Meazza R, Coppolecchia M et al. IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Therapy 1997; 4: 1029-1035.
28. Batra RK, Lin A, Sharma S et al. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism. Cancer Res 2003; 63: 642-646.
29. Torre-Amione G, Beauchamp RD, Koeppen H et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87: 1486-1490.
30. Masui T, Wakefield LM, Lechner JF et al. Type-beta transforming growth-factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial-cells. Proc Natl Acad Sci USA 1986; 83: 2438-2442.
31. Liu VC, Wong LY, Jang T et al. Tumor evasion of the immune system by converting CD4(+) CD25(-) T cells into CD4(+) CD25(+) T regulatory cells: role of tumorderived TGF-beta. J Immunol 2007; 178: 2883-2892.
32. Hasegawa Y, Takanashi S, Kanehira Y et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001; 91: 964-971.
33. Sharma S, Stolina M, Lin Y et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999; 163: 5020-5028.
34. Spagnoli GC, Juretic A, Schultzthater E et al. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer-cell activity. Cell Immunol 1993; 146: 391-405.
35. Huang M, Sharma S, Mao JT, Dubinett SM. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996; 157: 5512-5520.
36. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207-212.
37. Nishimura H, Nose M, Hiai H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
38. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30: 2046-2054.
39. Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168: 4272-4276.
40. Wolf AM, Wolf D, Steurer M et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606-612.
41. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
42. Srivastava MK, Zhu L, Harris-White M et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012; 7:e40677.
43. Liu X, Shin N, Koblish HK et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010; 115: 3520-3530.
44. Gan HK, You B, Pond GR, Chen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst 2012; 104: 590-598.
45. Sistigu A, Viaud S, Chaput N et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33: 369-383.
46. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14: 6674-6682.
47. Locher C, Conforti R, Aymeric L et al. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 2010; 1209: 99-108.
48. Garrison K, Hahn T, Lee WC et al. The small molecule TGF-beta signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother 2012; 61: 511-521.
49. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-4513.
50. Brahmer JR HL, Gandhi G et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. J Clin Oncol 2014; 32 (5s suppl): abstr 8112.
51. Binder DC, Engels B, Arina A et al. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject longestablished cancer. Cancer Immunol Res 2013; 1: 123-133.
52. Golden EB, Demaria S, Schiff PB et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1: 365-372.
53. Kandalaft LE, Tanyi J, Chiang C et al. Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer. J Immunother Cancer 2013; 1(Suppl 1): 220.
54. Tesniere A, Panaretakis T, Kepp O et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15: 3-12.
55. Tang C, Wang X, Soh H et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2014; 2: 831-838.
56. Nesslinger NJ, Ng A, Tsang KY et al. A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res 2010; 16: 4046-4056.
57. Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D et al. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol 2012; 2012: 741741.
58. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002; 2: 372-377.
59. Kalra R, Singh SP, Savage SM et al. Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores. J Pharmacol Exp Ther 2000; 293: 166-171.
60. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 2009; 9: 377-384.
61. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567.
62. Zhang J, Fujimoto J, Zhang J et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014; 346: 256-259.
63. Akbay EA, Koyama S, Carretero J et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-1363.
64. Azuma K, Ota K, Kawahara A et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014; 25: 1935-1940.
65. Xu C, Fillmore CM, Koyama S et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014; 25: 590-604.